Hemeoxygenase-1 in thyroid cancer progression

ALONSO, E.G.; PICHEL, P.; MASCARÓ, M.; FERNÁNDEZ CHÁVEZ, L.; PERÓS, I.G.; SCHWEITZER, K.; COLÓ, G.P.; RECIO, S.; CARBALLIDO, J.A.; ARÉVALO, J.; CASTELLANO, L.; FACCHINETTI, M.M.; GANDINI, N.A.; CURINO, A.C.

Congreso; Reunión Anual de Sociedades de Biociencia; 2020

Previous work from our group shows that Hemeoxygenase-1 (HO-1) is overexpressed in several types of tumor and the enzyme can be located in cell cytoplasm and/or nucleus. This subcellular distribution is caused by the cleavage of the C-terminus of HO-1 by calpain 1 (CAPN1), calpain 2 (CAPN2), cathepsin B (CTSB) and signal peptide peptidase (SPP). In thyroid cancer (TC), HO-1 potential utility as biomarker remains underexplored. The aim of this work was to study HO-1 expression in TC and its correlation with clinical-pathological data. Tumor biopsies (N=64) and fine needle aspiration biopsies (FNAB) (N=22) were used to asses HO-1 expression by inmunohistochemistry (IHC) and inmunocytochemistry (ICC), respectively. In addition, mRNA expression of HO-1, CAPN1, CAPN2, CTSB and SPP were analyzed by using GEPIA2 and Kaplan-Meier Plotter databases in in silico assays. In TC biopsies, overexpression (OE) of HO-1 by IHC was found in the tumor (T) respect to non-malignant areas to the tumor (NMT) (Mann Whitney test, p